T.B. Powles

Featured in: Favicon

Articles

The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?

Mar 13, 2024 | authors.elsevier.com | S. Gupta |T.B. Powles |B. Perez Valderrama |L. Sengelov

On October 22, 2023, results from the phase 3 trials EV-302, comparing enfortumab vedotin plus pembrolizumab (EV + P) with chemotherapy, and CheckMate 901, comparing gemcitabine, cisplatin, and nivolumab with chemotherapy alone, in metastatic urothelial carcinoma (mUC) were presented at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain [1], [2].

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.